Progen Pharmaceuticals Limited, a biotechnology company, engages in the discovery, development, and commercialization of small molecule therapeutics primarily for the treatment of cancer. Products PI-88 PI-88 is a carbohydrate-based small-molecule, which is believed to work through two mechanisms. Firstly, it inhibits the enzyme heparanase, which plays a primary role in tumor spread and invasion through surrounding tissues. Secondly, PI-88 exerts an anti-angiogenic effect by inhibiting the interaction between growth factors, heparan sulfate, and cellular receptors. The company has a license and collaboration agreement has been executed with Medigen Biotechnology Corporation (Medigen) for the development and commercialization of muparfostat worldwide. The agreement grants Medigen worldwide and sub-license rights for the commercialization of muparfostat for the therapeutic and prophylactic treatment of cancer. The company has an exclusive worldwide license from the Australian National University in Canberra, Australia, to five families of patents and patent applications relating to PI-88, its sulfated oligosaccharide heparanase inhibitor. Its license rights terminate in 2026. PG545 PG545 is a proprietary synthetic small molecule created to modulate the tumour microenvironment through multiple mechanisms of action. In 2014, the company completed treatment of the first patient cohort where each patient in this group received once-weekly 25mg doses of PG545. PharmaSynth Pty Ltd (PharmaSynth) PharmaSynth, a subsidiary of the company, provides contract pharmaceutical manufacturing development services to the biotechnology industry; and manufactures material for phase 1 to phase 3 clinical trials, as well as manufactures veterinary and animal health products. Trademarks Progen is a registered trademark of the company. History The company was founded in 1989. It was incorporated in 1989 as Almagest Pty. Ltd. in the state of Queensland, Australia. The company changed its name to Progen Industries Pty. Ltd. in 1990 and then to Progen Industries Limited in 1991. Further, the company changed its name to Progen Pharmaceuticals Limited in 2007.
progen pharmaceuticals ltd
(PGL:Australian Stock Exchange Ltd)
2806 Ipswich Road
Darra, QLD 4076
Phone: 61 7 3273 9133
Fax: 61 7 3375 1168www.progen-pharma.com
|No competitor information is available for PGL.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PROGEN PHARMACEUTICALS LTD, please visit www.progen-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.